Endovascular Orifice Detection (EOrD) Device for in situ Fenestration of Abdominal Aortic Aneurysm

用于腹主动脉瘤原位开窗的血管内孔口检测 (EOrD) 装置

• 批准号: 10612075
• 负责人: Mohammad Hamed Eslami
• 金额: $ 22.97万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-20 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10612075
• 关键词: Abdominal Aortic Aneurysm; Address; Anatomy; Aneurysm; Angiography; Annual Reports; Aorta; Aortic Aneurysm; Aortic Injury; Arteries; Blood; Blood flow; Cadaver; Catheters; Cause of Death; Cessation of life; Chest; Clinical; Complex; Consumption; Custom; Detection; Development; Devices; Diameter; Dilatation - action; FDA approved; Feedback; Geometry; Healthcare; Image; In Situ; In Vitro; Kidney; Lasers; Left; Liquid substance; Marketing; Mechanics; Medical Device; Methods; Neck; Operative Surgical Procedures; Organ Transplantation; Patients; Perfusion; Physiologic pulse; Population; Procedures; Psychological reinforcement; Pump; Puncture procedure; Radiation; Recovery; Reporting; Reproducibility; Risk; Rupture; Sheep; Signal Transduction; Stents; Superior mesenteric artery structure; Techniques; Testing; Time; United States; Vascularization; Visceral; analog; celiac artery; chelation; comorbidity; cooking; cost; design; digital; experimental study; fabrication; high risk; iliac artery; improved; innovation; iterative design; mechanical load; meetings; minimally invasive; mortality; novel; phantom model; prototype; renal artery; repaired; research and development; response; scale up; seal; sensor; success

Project Summary Abdominal aortic aneurysm (AAA) is a localized dilatation of the aorta and if left untreated may go on to rupture which is associated with a 90% mortality rate. This is the 15th leading cause of death in the United States with more than 15,000 annual deaths reported annually. When an aneurysm reaches the maximum diameter criteria (greater than 5.0 – 5.5 cm), clinicians will intervene with either open surgery or endovascular repair (EVAR). For complex AAA cases, a minimally invasive fenestrated EVAR (FEVAR) is preferred over high-risk open surgery, however, fenestrated stent-grafts extend past the visceral arteries (renal, superior mesenteric artery and celiac artery) and must be revascularized after deployment requiring the stent-graft to be prefabricated. Currently, there is only one FDA approved fenestrated graft on the market, the Cook Zenith Graft, that requires additional imaging for fabrication with a 6 - 8 week delivery time, costs up to 3 times more than traditional EVAR stent-grafts and can be technically challenging when passing guidewires through the orifices of the fenestrations. The objective of this project is to develop a medical device for endovascular orifice detection (EOrD) which will both locate visceral arteries and perform in situ fenestration. This device can then be applied in the use cases of AAA, ascending aneurysms, and traumatic aortic injury. Preliminary in vitro experiments were performed to determine whether visceral arteries could be detected through chelated sheep blood and stent-graft material using infrared (IR) waves. A scaled-up sensor array was built using phototransistors along with an analog to digital converter to detect the reflected IR waves. Distinct signal responses were collected while sweeping the sensor array over the orifice of the visceral artery, confirming feasibility. After an orifice of the visceral artery is detected, we plan to create a fenestration using a low-powered laser or mechanical puncturing mechanism that simultaneously inserts a guidewire to deploy the bridging stents. Our initial EOrD prototype with the proposed approach will be delivered through a catheter sheath and tested for orifice detection, puncture, and guidewire insertion using realistic in vitro AAA phantoms and cadavers. Continuous feedback from our clinical experts will improve design iterations to develop a final prototype that is able to reliably and reproducibly perform in situ fenestration of stent-grafts to treat aortic aneurysms. With our novel device, we can improve patient healthcare and reduce overall costs associated with AAA repair.

项目总结